In a report released today, Michael Matson from Needham maintained a Buy rating on Masimo (MASI – Research Report), with a price target of $173.00. The company’s shares closed yesterday at $153.45.
Matson covers the Healthcare sector, focusing on stocks such as Masimo, Atricure, and Boston Scientific. According to TipRanks, Matson has an average return of 1.9% and a 49.60% success rate on recommended stocks.
Masimo has an analyst consensus of Strong Buy, with a price target consensus of $166.40, implying an 8.44% upside from current levels. In a report released yesterday, BTIG also reiterated a Buy rating on the stock with a $180.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $262.28 and a one-year low of $108.89. Currently, Masimo has an average volume of 592.9K.
Based on the recent corporate insider activity of 15 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of MASI in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Masimo Corp. is a medical technology company, which develops, manufactures and markets non invasive patient monitoring technologies, medical devices and sensors. Its products include continuous monitors, patient-worn monitors, hospital automation connectivity, capnography & gas, data download & analytics and sensors & accessories. The company was founded by Joe E. Kiani in May 1989 and is headquartered in Irvine, CA.
Read More on MASI: